MovDisordV3, Main, Exploration, bibRecord, 004A78

Endogenous dopaminergic tone and dopamine agonist action

Identifieur interne : 004A78 ( Main/Exploration ); précédent : 004A77; suivant : 004A79

Endogenous dopaminergic tone and dopamine agonist action

Auteurs : Sarah A. Treseder [Royaume-Uni] ; Lance A. Smith [Royaume-Uni] ; Peter Jenner [Royaume-Uni]

Source :

Movement Disorders [ 0885-3185 ] ; 2000-09.

RBID : ISTEX:006B12F5208BEB368B47A3A289A7754BE272BE10

Descripteurs français

Pascal (Inist)
- A-77636, Agoniste, Animal adulte, Antiparkinsonien, Apomorphine, Dopamine, Inhibiteur enzyme, Lévodopa, Mécanisme action, Quinpirole, Récepteur dopaminergique D1, Récepteur dopaminergique D2, Singe, Stimulant dopaminergique, Traitement, Tyrosine 3-monooxygenase.
Wicri :
- topic : Singe.

English descriptors

KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (adverse effects), Adamantane (analogs & derivatives), Adamantane (pharmacology), Adult animal, Agonist, Animals, Antiparkinson Agents (pharmacology), Antiparkinson agent, Antiparkinsonian activity, Apomorphine (pharmacology), Benzopyrans (pharmacology), Callithrix, Common marmosets, D1 Dopamine receptor, D2 Dopamine receptor, Dopamine, Dopamine Agents (adverse effects), Dopamine Agents (pharmacology), Dopamine Agonists (pharmacology), Dopamine agonist, Dopamine receptor agonists, Dopaminergic tone, Dyskinesia, Drug-Induced (drug therapy), Dyskinesia, Drug-Induced (physiopathology), Enzyme Inhibitors (adverse effects), Enzyme inhibitor, Female, Levodopa, Levodopa (metabolism), Levodopa (pharmacology), Locomotion (drug effects), MPTP, Male, Mechanism of action, Monkey, Quinpirole, Quinpirole (pharmacology), Receptors, Dopamine D1 (agonists), Receptors, Dopamine D1 (drug effects), Receptors, Dopamine D2 (agonists), Receptors, Dopamine D2 (drug effects), Treatment, Tyrosine 3-Monooxygenase (antagonists & inhibitors), Tyrosine 3-monooxygenase, alpha-Methyltyrosine (adverse effects).
MESH :
- chemical , adverse effects : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Dopamine Agents, Enzyme Inhibitors, alpha-Methyltyrosine.
- chemical , agonists : Receptors, Dopamine D1, Receptors, Dopamine D2.
- chemical , analogs & derivatives : Adamantane.
- chemical , antagonists & inhibitors : Tyrosine 3-Monooxygenase.
- chemical , drug effects : Receptors, Dopamine D1, Receptors, Dopamine D2.
- chemical , metabolism : Levodopa.
- chemical , pharmacology : Adamantane, Antiparkinson Agents, Apomorphine, Benzopyrans, Dopamine Agents, Dopamine Agonists, Levodopa, Quinpirole.
- drug effects : Locomotion.
- drug therapy : Dyskinesia, Drug-Induced.
- physiopathology : Dyskinesia, Drug-Induced.
- Animals, Callithrix, Female, Male.

Abstract

Dopamine receptor agonists provide symptomatic relief in the early stages of Parkinson's disease, but with disease progression, their efficacy decreases. The reason behind this decrease in effectiveness is unknown, but maximal efficacy may be dependent on endogenous dopaminergic tone to provide stimulation of D1 and D2 receptor subtypes. Therefore, we have investigated the effects of the tyrosine hydroxylase inhibitor α‐methyl‐p‐tyrosine (AMPT) on the actions of D1, D2, and D1/D2 agonists and levodopa (L‐dopa) in common marmosets treated with 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine. Administration of AMPT alone further increased motor disability and decreased locomotor activity. Administration of L‐dopa reversed motor disability and increased locomotor activity, and this reversal was not affected by previous AMPT treatment. The D1 agonist A‐77636 and the D2 agonist quinpirole reversed motor deficits, but these effects were markedly inhibited by previous AMPT treatment. Administration of quinpirole with A‐77636 produced a reversal of motor deficits that was more resistant to AMPT pretreatment than was the effect produced by quinpirole or A‐77636 alone. These data suggest that D1 and D2 receptor stimulation are required for dopamine receptor agonists to produce a maximal antiparkinsonian response. The reversal of motor deficits produced by the mixed D1/D2 agonist apomorphine was more resistant to AMPT treatment than that produced by quinpirole or A‐77636. However, the motor effects of A‐77636 plus quinpirole and of apomorphine were still affected by AMPT treatment. This suggests that loss of tyrosine hydroxylase activity may also alter motor activity through inhibition of endogenous L‐dopa or norepinephrine synthesis, because both are also involved in the genesis of motor activity.

Url:

https://api.istex.fr/document/006B12F5208BEB368B47A3A289A7754BE272BE10/fulltext/pdf

DOI: 10.1002/1531-8257(200009)15:5<804::AID-MDS1007>3.0.CO;2-2

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Endogenous dopaminergic tone and dopamine agonist action</title>
<author><name sortKey="Treseder, Sarah A" sort="Treseder, Sarah A" uniqKey="Treseder S" first="Sarah A." last="Treseder">Sarah A. Treseder</name>
</author>
<author><name sortKey="Smith, Lance A" sort="Smith, Lance A" uniqKey="Smith L" first="Lance A." last="Smith">Lance A. Smith</name>
</author>
<author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:006B12F5208BEB368B47A3A289A7754BE272BE10</idno>
<date when="2000" year="2000">2000</date>
<idno type="doi">10.1002/1531-8257(200009)15:5<804::AID-MDS1007>3.0.CO;2-2</idno>
<idno type="url">https://api.istex.fr/document/006B12F5208BEB368B47A3A289A7754BE272BE10/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000126</idno>
<idno type="wicri:Area/Istex/Curation">000126</idno>
<idno type="wicri:Area/Istex/Checkpoint">003278</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Treseder S:endogenous:dopaminergic:tone</idno>
<idno type="wicri:Area/Main/Merge">007375</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:00-0481192</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002B36</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000185</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002C10</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Treseder S:endogenous:dopaminergic:tone</idno>
<idno type="wicri:Area/Main/Merge">007602</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:11009183</idno>
<idno type="wicri:Area/PubMed/Corpus">003F22</idno>
<idno type="wicri:Area/PubMed/Curation">003F22</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003F89</idno>
<idno type="wicri:Area/Ncbi/Merge">000329</idno>
<idno type="wicri:Area/Ncbi/Curation">000329</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000329</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Treseder S:endogenous:dopaminergic:tone</idno>
<idno type="wicri:Area/Main/Merge">007132</idno>
<idno type="wicri:Area/Main/Curation">004A78</idno>
<idno type="wicri:Area/Main/Exploration">004A78</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Endogenous dopaminergic tone and dopamine agonist action</title>
<author><name sortKey="Treseder, Sarah A" sort="Treseder, Sarah A" uniqKey="Treseder S" first="Sarah A." last="Treseder">Sarah A. Treseder</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Neurodegenerative Disease Research Centre, Guy's, King's, and St. Thomas's School of Biomedical Sciences, King's College London, Guy's Campus, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Smith, Lance A" sort="Smith, Lance A" uniqKey="Smith L" first="Lance A." last="Smith">Lance A. Smith</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Neurodegenerative Disease Research Centre, Guy's, King's, and St. Thomas's School of Biomedical Sciences, King's College London, Guy's Campus, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Neurodegenerative Disease Research Centre, Guy's, King's, and St. Thomas's School of Biomedical Sciences, King's College London, Guy's Campus, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2000-09">2000-09</date>
<biblScope unit="vol">15</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="804">804</biblScope>
<biblScope unit="page" to="812">812</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">006B12F5208BEB368B47A3A289A7754BE272BE10</idno>
<idno type="DOI">10.1002/1531-8257(200009)15:5<804::AID-MDS1007>3.0.CO;2-2</idno>
<idno type="ArticleID">MDS1007</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (adverse effects)</term>
<term>Adamantane (analogs & derivatives)</term>
<term>Adamantane (pharmacology)</term>
<term>Adult animal</term>
<term>Agonist</term>
<term>Animals</term>
<term>Antiparkinson Agents (pharmacology)</term>
<term>Antiparkinson agent</term>
<term>Antiparkinsonian activity</term>
<term>Apomorphine (pharmacology)</term>
<term>Benzopyrans (pharmacology)</term>
<term>Callithrix</term>
<term>Common marmosets</term>
<term>D1 Dopamine receptor</term>
<term>D2 Dopamine receptor</term>
<term>Dopamine</term>
<term>Dopamine Agents (adverse effects)</term>
<term>Dopamine Agents (pharmacology)</term>
<term>Dopamine Agonists (pharmacology)</term>
<term>Dopamine agonist</term>
<term>Dopamine receptor agonists</term>
<term>Dopaminergic tone</term>
<term>Dyskinesia, Drug-Induced (drug therapy)</term>
<term>Dyskinesia, Drug-Induced (physiopathology)</term>
<term>Enzyme Inhibitors (adverse effects)</term>
<term>Enzyme inhibitor</term>
<term>Female</term>
<term>Levodopa</term>
<term>Levodopa (metabolism)</term>
<term>Levodopa (pharmacology)</term>
<term>Locomotion (drug effects)</term>
<term>MPTP</term>
<term>Male</term>
<term>Mechanism of action</term>
<term>Monkey</term>
<term>Quinpirole</term>
<term>Quinpirole (pharmacology)</term>
<term>Receptors, Dopamine D1 (agonists)</term>
<term>Receptors, Dopamine D1 (drug effects)</term>
<term>Receptors, Dopamine D2 (agonists)</term>
<term>Receptors, Dopamine D2 (drug effects)</term>
<term>Treatment</term>
<term>Tyrosine 3-Monooxygenase (antagonists & inhibitors)</term>
<term>Tyrosine 3-monooxygenase</term>
<term>alpha-Methyltyrosine (adverse effects)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term>
<term>Dopamine Agents</term>
<term>Enzyme Inhibitors</term>
<term>alpha-Methyltyrosine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="agonists" xml:lang="en"><term>Receptors, Dopamine D1</term>
<term>Receptors, Dopamine D2</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Adamantane</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Tyrosine 3-Monooxygenase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Dopamine D1</term>
<term>Receptors, Dopamine D2</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Adamantane</term>
<term>Antiparkinson Agents</term>
<term>Apomorphine</term>
<term>Benzopyrans</term>
<term>Dopamine Agents</term>
<term>Dopamine Agonists</term>
<term>Levodopa</term>
<term>Quinpirole</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Locomotion</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Callithrix</term>
<term>Female</term>
<term>Male</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>A-77636</term>
<term>Agoniste</term>
<term>Animal adulte</term>
<term>Antiparkinsonien</term>
<term>Apomorphine</term>
<term>Dopamine</term>
<term>Inhibiteur enzyme</term>
<term>Lévodopa</term>
<term>Mécanisme action</term>
<term>Quinpirole</term>
<term>Récepteur dopaminergique D1</term>
<term>Récepteur dopaminergique D2</term>
<term>Singe</term>
<term>Stimulant dopaminergique</term>
<term>Traitement</term>
<term>Tyrosine 3-monooxygenase</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Singe</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Dopamine receptor agonists provide symptomatic relief in the early stages of Parkinson's disease, but with disease progression, their efficacy decreases. The reason behind this decrease in effectiveness is unknown, but maximal efficacy may be dependent on endogenous dopaminergic tone to provide stimulation of D1 and D2 receptor subtypes. Therefore, we have investigated the effects of the tyrosine hydroxylase inhibitor α‐methyl‐p‐tyrosine (AMPT) on the actions of D1, D2, and D1/D2 agonists and levodopa (L‐dopa) in common marmosets treated with 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine. Administration of AMPT alone further increased motor disability and decreased locomotor activity. Administration of L‐dopa reversed motor disability and increased locomotor activity, and this reversal was not affected by previous AMPT treatment. The D1 agonist A‐77636 and the D2 agonist quinpirole reversed motor deficits, but these effects were markedly inhibited by previous AMPT treatment. Administration of quinpirole with A‐77636 produced a reversal of motor deficits that was more resistant to AMPT pretreatment than was the effect produced by quinpirole or A‐77636 alone. These data suggest that D1 and D2 receptor stimulation are required for dopamine receptor agonists to produce a maximal antiparkinsonian response. The reversal of motor deficits produced by the mixed D1/D2 agonist apomorphine was more resistant to AMPT treatment than that produced by quinpirole or A‐77636. However, the motor effects of A‐77636 plus quinpirole and of apomorphine were still affected by AMPT treatment. This suggests that loss of tyrosine hydroxylase activity may also alter motor activity through inhibition of endogenous L‐dopa or norepinephrine synthesis, because both are also involved in the genesis of motor activity.</div>
</front>
</TEI>
<affiliations><list><country><li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Grand Londres</li>
</region>
<settlement><li>Londres</li>
</settlement>
</list>
<tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Treseder, Sarah A" sort="Treseder, Sarah A" uniqKey="Treseder S" first="Sarah A." last="Treseder">Sarah A. Treseder</name>
</region>
<name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name>
<name sortKey="Smith, Lance A" sort="Smith, Lance A" uniqKey="Smith L" first="Lance A." last="Smith">Lance A. Smith</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004A78 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004A78 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:006B12F5208BEB368B47A3A289A7754BE272BE10
   |texte=   Endogenous dopaminergic tone and dopamine agonist action
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Endogenous dopaminergic tone and dopamine agonist action

Endogenous dopaminergic tone and dopamine agonist action

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.